PEG-ADA2-K374D

PEG-ADA2-K374D is a pegylated, engineered recombinant human adenosine deaminase 2 (ADA2) variant developed by Halozyme Therapeutics for the treatment of solid tumors. Adenosine is an endogenous immunosuppressant that accumulates at high levels within the tumor microenvironment (TME), where it binds to adenosine receptors on immune cells to inhibit anti-tumor responses. PEG-ADA2-K374D is designed to enzymatically deplete TME adenosine by catalyzing its deamination into inosine. The K374D mutation was introduced to attenuate the enzyme's heparin-binding properties, thereby improving its biodistribution and pharmacokinetic profile. Furthermore, the protein is conjugated with a 20 kDa polyethylene glycol (PEG) moiety to extend its circulating half-life. Preclinical studies in syngeneic mouse models demonstrated that PEG-ADA2-K374D treatment leads to significant tumor growth inhibition and increased infiltration of CD3+ T-cells into the tumor.

Other names

pegylated engineered adenosine deaminase 2PEG-ADA2PEG-ADA-2PEG-ADA 2